BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11466359)

  • 1. Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system.
    Kunisawa J; Nakanishi T; Takahashi I; Okudaira A; Tsutsumi Y; Katayama K; Nakagawa S; Kiyono H; Mayumi T
    J Immunol; 2001 Aug; 167(3):1406-12. PubMed ID: 11466359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.
    Hagiwara Y; McGhee JR; Fujihashi K; Kobayashi R; Yoshino N; Kataoka K; Etani Y; Kweon MN; Tamura S; Kurata T; Takeda Y; Kiyono H; Fujihashi K
    J Immunol; 2003 Feb; 170(4):1754-62. PubMed ID: 12574339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
    Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
    J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production.
    Yanagita M; Hiroi T; Kitagaki N; Hamada S; Ito HO; Shimauchi H; Murakami S; Okada H; Kiyono H
    J Immunol; 1999 Mar; 162(6):3559-65. PubMed ID: 10092814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration.
    Sekine S; Kataoka K; Fukuyama Y; Adachi Y; Davydova J; Yamamoto M; Kobayashi R; Fujihashi K; Suzuki H; Curiel DT; Shizukuishi S; McGhee JR; Fujihashi K
    J Immunol; 2008 Jun; 180(12):8126-34. PubMed ID: 18523277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway.
    Nakanishi T; Hayashi A; Kunisawa J; Tsutsumi Y; Tanaka K; Yashiro-Ohtani Y; Nakanishi M; Fujiwara H; Hamaoka T; Mayumi T
    Eur J Immunol; 2000 Jun; 30(6):1740-7. PubMed ID: 10898512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
    Krishnan L; Sad S; Patel GB; Sprott GD
    J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma vaccine based on the vector of membrane fusogenic liposomes.
    Qiang L; Yi J; Fu-De C
    Pharmazie; 2004 Apr; 59(4):263-7. PubMed ID: 15125569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of antigen-specific immune responses using DNA-fusogenic liposome vaccine.
    Yoshikawa T; Imazu S; Gao JQ; Hayashi K; Tsuda Y; Shimokawa M; Sugita T; Niwa T; Oda A; Akashi M; Tsutsumi Y; Mayumi T; Nakagawa S
    Biochem Biophys Res Commun; 2004 Dec; 325(2):500-5. PubMed ID: 15530420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation.
    Harding CV; Collins DS; Kanagawa O; Unanue ER
    J Immunol; 1991 Nov; 147(9):2860-3. PubMed ID: 1918996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel vaccine delivery system using immunopotentiating fusogenic liposomes.
    Hayashi A; Nakanishi T; Kunisawa J; Kondoh M; Imazu S; Tsutsumi Y; Tanaka K; Fujiwara H; Hamaoka T; Mayumi T
    Biochem Biophys Res Commun; 1999 Aug; 261(3):824-8. PubMed ID: 10441509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MHC class II-peptide complexes in dendritic cell lipid microdomains initiate the CD4 Th1 phenotype.
    Buatois V; Baillet M; Bécart S; Mooney N; Leserman L; Machy P
    J Immunol; 2003 Dec; 171(11):5812-9. PubMed ID: 14634090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of specific IgE antibody responses by liposome-conjugated ovalbumin in mice sensitized with ovalbumin via the respiratory tract.
    Yoshikawa T; Uchida T; Naito S; Horino A; Taneichi M; Kato H; Komuro K; Nakano Y; Mori M; Nishinohara S; Chiba J; Kurata T; Tamura S
    Int Arch Allergy Immunol; 2000 Feb; 121(2):108-15. PubMed ID: 10705220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANTES potentiates antigen-specific mucosal immune responses.
    Lillard JW; Boyaka PN; Taub DD; McGhee JR
    J Immunol; 2001 Jan; 166(1):162-9. PubMed ID: 11123289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.
    Ishii M; Kojima N
    Glycoconj J; 2010 Jan; 27(1):115-23. PubMed ID: 19816665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of systemic and mucosal immune response following nasal administration of liposomes.
    Aramaki Y; Fujii Y; Yachi K; Kikuchi H; Tsuchiya S
    Vaccine; 1994 Oct; 12(13):1241-5. PubMed ID: 7839731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.
    Watarai S; Iwase T; Tajima T; Yuba E; Kono K
    ScientificWorldJournal; 2013; 2013():903234. PubMed ID: 23431260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.
    Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H
    Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.
    Ebensen T; Libanova R; Schulze K; Yevsa T; Morr M; Guzmán CA
    Vaccine; 2011 Jul; 29(32):5210-20. PubMed ID: 21619907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.